US Patent

US11890270 — Polymorphic forms of ST-246 and methods of preparation

Method of Use · Assigned to Siga Technologies Inc · Expires 2032-08-08 · 6y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent discloses polymorphic forms of ST-246 and their methods of preparation, as well as methods of synthesis and pharmaceutical compositions.

USPTO Abstract

Polymorph forms of 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide are disclosed as well as their methods of synthesis and pharmaceutical compositions.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2346`	—

Patent Metadata

Patent number: US11890270
Jurisdiction: US
Classification: Method of Use
Expires: 2032-08-08
Drug substance claim: No
Drug product claim: No
Assignee: Siga Technologies Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.